ReviewClinical ophthalmology (Auckland, N.Z.)2016
Critical evaluation of latanoprostene bunod in the treatment of glaucoma.
Review in Clinical ophthalmology (Auckland, N.Z.), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 45 citations in OpenAlex.
- Evaluation of the IOP-Lowering Effect of a Multi-Pressure Dial at Different Negative Pressure Settings.Translational vision science & technology · 2020Trial
- Netarsudil-Induced Honeycomb Keratopathy in an Eye With Iridocorneal Endothelial Syndrome.Case reports in ophthalmological medicine · 2026Article
- Effects of 0.024% latanoprostene bunod on intraocular pressure and pupil diameter in normal cats and cats with congenital glaucoma.Veterinary ophthalmology · 2026Article
- Integrating neuroprotection, antioxidative effects, and precision medicine in glaucoma management with bioactive compounds.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2025Review
- Marine Phytoplankton Bioactive Lipids and Their Perspectives in Clinical Inflammation.Marine drugs · 2025Review
- Real-world impact of latanoprostene bunod ophthalmic solution 0.024% in glaucoma therapy: a narrative review.Frontiers in ophthalmology · 2025Review
- The Application of Nitric Oxide for Ocular Hypertension Treatment.Molecules (Basel, Switzerland) · 2021Review
- Novel Thiol Containing Hybrid Antioxidant-Nitric Oxide Donor Small Molecules for Treatment of Glaucoma.Antioxidants (Basel, Switzerland) · 2021Article
- Deconstructing aqueous humor outflow - The last 50 years.Experimental eye research · 2020Review
- Newly Developed Prodrugs and Prodrugs in Development; an Insight of the Recent Years.Molecules (Basel, Switzerland) · 2020Review
- Cell senescence altered the miRNA expression profile in porcine angular aqueous plexus cells.Molecular vision · 2020Article
- Treatment choices for newly diagnosed primary open angle and ocular hypertension patients.Eye (London, England) · 2020Review
- New glaucoma medications: latanoprostene bunod, netarsudil, and fixed combination netarsudil-latanoprost.Eye (London, England) · 2020Review
- Prostaglandin analogues and nitric oxide contribution in the treatment of ocular hypertension and glaucoma.British journal of pharmacology · 2019Review
- The expanding role of prodrugs in contemporary drug design and development.Nature reviews. Drug discovery · 2018Review
- The nitric oxide-guanylate cyclase pathway and glaucoma.Nitric oxide : biology and chemistry · 2018Review
- Novel Therapeutics in Glaucoma Management.Current neuropharmacology · 2018Review
- Effect of Cromakalim Prodrug 1 (CKLP1) on Aqueous Humor Dynamics and Feasibility of Combination Therapy With Existing Ocular Hypotensive Agents.Investigative ophthalmology & visual science · 2017Article
- Effects of Novel Nitric Oxide-Releasing Molecules against Oxidative Stress on Retinal Pigmented Epithelial Cells.Oxidative medicine and cellular longevity · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Latanoprostene bunod (LBN) is a novel nitric oxide-donating prostaglandin F
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.